Carriers of pathogenic variants in MLH1 and MSH2 exhibit the highest overall cancer risks among individuals with Lynch syndrome, with cumulative cancer incidences of approximately 81% (♀)/ 71% (♂) and 84% (♀)/ 75% (♂) at the age of 75 [70]. Here, MSH2 is linked to cancer.